We are live on ! Find out more
TLP

Tri Locum Partners Portfolio holdings

AUM $713M
1-Year Est. Return 68.92%
This Fund
S&P 500
This Quarter Est. Return
+6.06%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$195M
AUM Growth
-$288M
Cap. Flow
-$284M
Cap. Flow %
-145.48%
Top 10 Hldgs %
73.17%
Holding
37
New
9
Increased
2
Reduced
10
Closed
15

Top Buys

Rank Stock Value
1
MCK icon
McKesson
MCK
+$16.7M
2
ILMN icon
Illumina
ILMN
+$13.1M
3
SLNO
Soleno Therapeutics
SLNO
+$11.4M
4
CI icon
Cigna
CI
+$9.97M
5
GILD icon
Gilead Sciences
GILD
+$9.23M

Top Sells

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$39M
2
NTRA icon
Natera
NTRA
+$32.1M
3
ARGX icon
argenx
ARGX
+$25.5M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$24.3M
5
VRNA
Verona Pharma
VRNA
+$21.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CI icon
1
Cigna
CI
$74.5B
$24.3M 12.48%
73,905
+33,095
+81% +$9.97M
MCK icon
2
McKesson
MCK
$98.5B
$18.1M 9.3%
+26,944
New +$16.7M
SLNO
3
DELISTED
Soleno Therapeutics
SLNO
$16.8M 8.61%
+234,920
New +$11.4M
TEVA icon
4
Teva Pharmaceuticals
TEVA
$37.3B
$16.3M 8.37%
1,061,008
-1,362,108
-56% -$24.3M
INSP icon
5
Inspire Medical Systems
INSP
$1.46B
$12.6M 6.44%
78,812
-71,976
-48% -$13M
MDGL icon
6
Madrigal Pharmaceuticals
MDGL
$12.8B
$12.5M 6.44%
37,869
-9,603
-20% -$3.16M
AXSM icon
7
Axsome Therapeutics
AXSM
$11.8B
$11.8M 6.06%
101,240
-148,529
-59% -$16.9M
ARGX icon
8
argenx
ARGX
$53.8B
$10.6M 5.42%
17,844
-40,414
-69% -$25.5M
GILD icon
9
Gilead Sciences
GILD
$167B
$10M 5.14%
+89,453
New +$9.23M
ILMN icon
10
Illumina
ILMN
$28.2B
$9.58M 4.91%
+120,729
New +$13.1M
INSM icon
11
Insmed
INSM
$23.5B
$7.77M 3.99%
+101,859
New +$7.79M
NUVL
12
DELISTED
Nuvalent
NUVL
$6.8M 3.49%
+95,825
New +$7.49M
MRUS
13
DELISTED
Merus
MRUS
$6.6M 3.39%
156,915
-190,388
-55% -$8.3M
WGS icon
14
GeneDx Holdings
WGS
$1.88B
$5.15M 2.64%
58,145
-69,422
-54% -$6.02M
ASND icon
15
Ascendis Pharma A/S
ASND
$17.1B
$5.04M 2.59%
+32,325
New +$4.62M
BPMC
16
DELISTED
Blueprint Medicines
BPMC
$4.43M 2.27%
+50,000
New +$4.88M
EOLS icon
17
Evolus
EOLS
$377M
$3.87M 1.99%
321,802
-420,772
-57% -$5.5M
VERA icon
18
Vera Therapeutics
VERA
$2.76B
$3.61M 1.85%
+150,207
New +$4.83M
STVN icon
19
Stevanato
STVN
$5.23B
$3.59M 1.84%
175,681
-946,123
-84% -$20.1M
PRAX icon
20
Praxis Precision Medicines
PRAX
$8.77B
$3.17M 1.63%
83,659
+46,390
+124% +$2.9M
KRRO icon
21
Korro Bio
KRRO
$177M
$2.24M 1.15%
128,381
-15,835
-11% -$470K
FEMY icon
22
Femasys
FEMY
$9.09M
$38.3K 0.02%
1,530
– –
AVDL
23
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-1,937,984
Closed -$20.4M
BHVN icon
24
Biohaven
BHVN
$2.32B
– –
-140,220
Closed -$5.24M
BMY icon
25
Bristol-Myers Squibb
BMY
$124B
– –
-355,366
Closed -$20.1M
1
2

Similar funds

DCM
Defilade Capital Management Emeryville, California $712M AUM
AMPWP
Alvarez & Marsal Private Wealth Partners West Palm Beach, Florida $712M AUM
DCM
Dimension Capital Management Coral Gables, Florida $713M AUM 18.57% 1-Year Est. Return
IWP
Insight Wealth Partners Plano, Texas $713M AUM 16.55% 1-Year Est. Return
LS
Leelyn Smith Geneva, Illinois $713M AUM 17.46% 1-Year Est. Return
PCS
Personal CFO Solutions Chester, New Jersey $712M AUM 25.3% 1-Year Est. Return
ACGDR
Atmos Capital Gestao de Recursos Leblon - Rio De Janeiro, Brazil $714M AUM 35.97% 1-Year Est. Return
GEA
Glen Eagle Advisors Kingston, New Jersey $714M AUM 18.87% 1-Year Est. Return

Tri Locum Partners's Q1 2025 Portfolio in Review

As of Q1 2025, Tri Locum Partners held 37 positions worth $195M, down 60% from $483M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Tri Locum Partners withdrew a net $284M in Q1 2025, closing 15 positions and reducing 10 holdings. Its most notable exit was Zimmer Biomet, an estimated $39M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Tri Locum Partners opened a new position in McKesson worth $18.1M.

  • Tri Locum Partners's largest Q1 2025 buy was McKesson: 26,944 shares worth $18.1M.
  • Tri Locum Partners added most to Cigna in Q1 2025, an estimated $9.97M increase.
  • Tri Locum Partners's biggest Q1 2025 reduction was argenx, cutting an estimated $25.5M.
  • Tri Locum Partners fully exited Zimmer Biomet in Q1 2025, selling an estimated $39M.
  • Tri Locum Partners's ten largest holdings make up 73% of its $195M portfolio in Q1 2025.
  • Tri Locum Partners opened 9 new positions and closed 15 in Q1 2025.
  • Tri Locum Partners's portfolio value fell 60% quarter-over-quarter to $195M.

Based on Tri Locum Partners's 13F filing for Q1 2025, filed 14 May 2025.